Canonic aims to develop and bring to market medical-grade cannabis using a genomic approach. The company will initially focus on creating improved cannabis varieties, focusing on yield, stability, and specific metabolite composition. The company is a subsidiary of Evogene. Canonics development efforts will be based on the utilization of Evogenes computational predictive biology platform, which has already demonstrated success in addressing similar objectives for other crops.